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Abstract 
Recently, novel antiandrogens and inhibitors of androgen biosynthesis have been developed 
through the elucidation of mechanisms of castration resistance of prostate cancer. We believe that 
these new developments will improve hormonal therapy. On the other hand there has been an 
increase in criticism of hormonal therapy, because hormonal therapy is supposed to induce adverse 
effects such as cardiovascular disease. In this review we have introduced the Japanese experience of 
hormonal therapy, because we believe that there may be ethnic differences between Caucasians and 
Asian people in the efficacy and adverse effects of hormonal therapy. 
 First we showed that primary hormonal therapy can achieve long-term control of localized 
prostate cancer in some cases and that quality of life of patients receiving hormonal therapy is rather 
better than previously thought. 
Neoadjuvant and adjuvant hormonal therapy in cases undergoing radical prostatectomy or 
radiotherapy are very useful for high-risk or locally advanced prostate cancer. Further clinical trials 
are required to confirm the efficacy of neoadjuvant or adjuvant hormonal therapy. 
We showed that the death from cardiovascular diseases in Japanese patients receiving hormonal 
therapy was not higher than that in the general population. However, efforts should be made to 
decrease the adverse effects of hormonal therapy, because life-style change may increase the 
susceptibility to adverse effects by hormonal therapy even in Japan. Managements of endocrine and 
metabolic dysfunction, such as diabetes mellitus, are essential. New hormonal compounds such as 
selective androgen receptor modulators capable of specifically targeting prostate cancer are expected 
to be developed. 
Introduction 
Hormonal therapy has played an important role in the treatment of prostate cancer since it was 
first introduced about 70 years ago by Huggins and Hodges1). At present, hormonal therapy is still 
used as the first choice of treatment for advanced prostate cancer. It is frequently used as 
neoadjuvant or adjuvant therapy in cases undergoing radical prostatectomy or radiotherapy. 
Furthermore hormonal therapy is sometimes the primary treatment for localized prostate cancer, 
especially in aged patients. Although widely used, hormonal therapy has recently been the subject of 
criticism. Some authors have reported that its effectiveness is minimal2), while others suggested that 
it may reduce patients’ quality of life (QOL) and induce adverse effects3, 4). Such reports should be 
evaluated very carefully. Accurate evaluation of the efficacy of primary hormonal therapy is very 
difficult, because many factors, such as the type of hormonal therapy used (i.e., castration alone, 
antiandrogen therapy, or combined androgen blockade), and the duration of hormonal therapy affect 
the outcome of treatment.  
In this review we have introduced Japanese experience of hormonal therapy for prostate cancer. 
 
Efficacy of primary hormonal therapy for localized or low-risk prostate cancer 
Hormonal therapy is not recommended as the primary treatment for localized prostate cancer 
according to representative guidelines, such as the National Comprehensive Cancer Network 
(NCCN) guidelines. However, according to the Japanese cancer registration statistics, many patients 
with localized prostate cancer have actually been treated with primary hormonal therapy5). Despite 
urologist’s explanation regarding the various treatments for localized prostate cancer, many patients 
select primary hormonal therapy6). It is likely that many patients with localized prostate cancer select 
primary hormonal therapy because medical treatment, such as primary hormonal therapy, is more 
acceptable than more invasive treatments, such as surgery, for many Japanese patients. In addition, 
urologists themselves may also influence patients’ decisions because they have experience of the 
effectiveness of primary hormonal therapy.  
The ethnic background of patients may play an important role in the effectiveness of hormonal 
therapy and in susceptibility to adverse effects. The efficacy of hormonal therapy has been compared 
between Japanese Americans and Caucasians living in Hawaii7). Both groups had similar 
backgrounds, but both overall and cause-specific survival rates of Japanese Americans were better 
than those of Caucasian subjects (Fig. 1). The overall survival rate was also compared among 
Caucasian, Chinese, and Filipino patients living in Hawaii. The Chinese subjects showed similar 
trends to Japanese patients. Therefore, sensitivity of prostate cancer to hormonal therapy and 
susceptibility to adverse effects may differ among ethnic groups. 
Akaza et al. reported that overall survival of patients with localized or locally advanced prostate 
cancer treated with primary hormonal therapy was equivalent to life expectancy of age-matched 
subjects in the healthy population8). Before Akaza’s report Egawa et al. had already reported that 
primary hormonal therapy was as effective as radical prostatectomy with regard to disease-specific 
survival rate in localized prostate cancer9). In their report, disease-specific survival rate at 10 years of 
56 patients with well-differentiated prostate cancer treated with primary hormonal therapy was 100%. 
Why is the outcome of primary hormonal therapy so excellent, especially in well-differentiated 
prostate cancer? Kitagawa et al. analyzed the histological effects of hormonal therapy in specimens 
from patients treated with radical prostatectomy after neoadjuvant hormonal therapy10). They 
reported that histologically cured or nearly cured patients accounted for more than 40% of the total 
number. In addition, the recurrence-free survival rate of the patients with histologically complete 
apoptosis was 100%. These results suggest that some cases of localized prostate cancer could be 
cured by primary hormonal therapy alone. Schulman et al. also performed neoadjuvant hormonal 
treatment for 3 months before radical prostatectomy in patients with localized prostate cancer, and 
reported good histological effects11). Labrie also reported that about 80% of Stage B prostate cancer 
could be controlled for long-term with primary hormonal therapy12). 
These reports raise questions about which groups of patients would be good candidates for 
primary hormonal therapy. We performed a retrospective review of the efficacy of primary hormonal 
therapy in 628 patients with localized or locally advanced prostate cancer treated with primary 
hormonal therapy at 7 institutions in Japan, and attempted to predict patients in whom the disease 
could be controlled for long periods by primary hormonal therapy13). Disease-specific and overall 
survival rates at 8 years in all patients were 89.1% and 75.0%, respectively. In addition, 
disease-specific survival rate at 8 years of patients given combined androgen blockade (CAB) 
treatment was 95.3%, which was significantly higher than that of patients treated with castration 
alone. We classified the patients into three risk groups based on pretreatment PSA level and Gleason 
score according to a modification of the D’Amico risk grouping14). Disease-specific survival rates at 
8 years of low-, intermediate-, and high-risk groups were 97.6%, 95.4%, and 78.3%, respectively 
(Fig. 2). Next, we divided low- and intermediate-risk patients into two groups with PSA level < 0.2 
ng/mL after hormonal therapy. The time to PSA level < 0.2 was within 6 months in 192 patients 
(good response group, Group G). These patients accounted for 30.6% of the total patient population. 
We classified the 139 patients in whom the PSA level did not fall below 0.2 within 6 months as the 
poor response group (Group P). The disease-specific survival rates at 8 years of Groups G and P 
were 98.9% and 94.0%, respectively. Notably, there were no cancer-related deaths during the 
observation period among the 133 patients in Group G receiving CAB treatment in this study. 
Although a randomized controlled trial may be necessary for utilization of primary hormonal therapy 
in patients in whom such treatment is considered more effective, based on the results of our study 
T1c-T3 patients with PSA level ≤ 20 ng/mL and Gleason score ≤ 7 may be good candidates for the 
initial hormonal therapy. These patients accounted for 52.7% of the total number of T1c-T3 patients 
in our study. Hormonal therapy may be suitable as the initial treatment in such patients, but changing 
to another curative regimen or combination therapy with radiotherapy or radical prostatectomy 
should be considered if the PSA value does not decrease to < 0.2 ng/mL after 6 months of hormonal 
therapy. However, in patients in whom the PSA value drops to < 0.2 ng/mL within 6 months of the 
commencement of hormonal therapy, continuation of the same regimen may be reasonable with 
careful observation (Fig. 3). 
Another preference for early-stage prostate cancer patients involves active surveillance. No study 
in PSA screened low risk cancer has ever found that treatment is better than no treatment. Therefore, 
further investigations are necessary to compare the disease-specific or progression-free survival rates 
of a low-risk group, such as Group G, with those of active surveillance group. The PIVOT trial has 
recently shown that radical prostatectomy did not reduce mortality any more than observation in men 
with low PSA or low risk prostate cancer. However, even cancer cells for which observation alone 
without treatment was at first thought to be sufficient are not always inactive after long periods. 
These cancer cells may become impossible to control due to malignant transformation by gene 
mutation during follow-up15). In addition, most patients are anxious about the status of their disease, 
and few are willing to rely solely on active surveillance16). Another possible problem is the period 
over which hormonal therapy should be continued. Labrie et al. performed long-term hormonal 
therapy in stage B and C patients and discontinued the treatment in patients who did not show PSA 
recurrence. An increase in PSA occurred in only 2 of 33 patients with stage B and C prostate cancer 
who stopped treatment after continuous CAB for more than 6.5 years. In addition, seven of eight 
patients with localized prostate cancer who received CAB treatment continuously for 6.5 – 9.0 years 
before stopping treatment showed no PSA failure at least 5 years after cessation of CAB. CAB 
treatment was restarted in patients showing PSA recurrence after cessation of the initial hormonal 
treatment, and control was achieved again in most cases. Thus, it was concluded that CAB treatment 
for 7 years may be suitable in such cases. Recently, Tanaka et al. also investigated when hormonal 
therapy could be discontinued based on nadir PSA levels after commencement of treatment. They 
concluded that a relatively short period, e.g., 3 years, may be sufficient in cases in which the nadir 
PSA dropped to < 0.01 ng/mL17). Although intermittent hormonal therapy was reported to be useful 
for the treatment of advanced prostate cancer to maintain sensitivity to androgens18), care is required 
in application of this treatment to localized prostate cancer as cancer that could be controlled over 
the long term or may be cured by appropriate hormonal therapy12) may progress to develop more 
malignant potential by incomplete androgen ablation.  
According to the modified D’Amico classification reported previously14), disease-specific and 
progression-free survival rates of the high-risk group treated with primary hormonal therapy at 5 
years were 87.8% and 58.8%, respectively. From these results long-term control by primary 
hormonal therapy seems difficult in the high-risk group. However, Mizokami et al.19) reanalyzed the 
previous data and showed that the results for the high-risk group are not necessarily pessimistic in 
patients in whose PSA value drops to < 0.2 ng/mL. They proposed that high-risk prostate cancer 
patients should be first treated with neoadjuvant CAB. Then, once a PSA value of < 0.2 has been 
reached, patients with favorable parameters (Gleason score ≤ 6, pretreatment PSA ≤ 20, time to 
PSA< 0.2 ng/mL within 6 months after the commencement of hormonal therapy) are likely to have 
less possibility (< 25%) of relapse at 10 years after commencement of CAB. Therefore, such patients 
could select any treatment option, e.g., surgery, radiotherapy, or primary hormonal therapy. However, 
they recommend that poor responders to neoadjuvant CAB should be treated with more intensive 
therapy using CAB combined with high dose rate (HDR)-brachytherapy, intensity-moderated 
radiotherapy (I-MRT), or some forms of chemotherapy. 
 
Issues of QOL and medical cost 
Long-term hormonal therapy is sometimes criticized for reducing patients’ QOL. In our 
institution, the QOL of prostate cancer patients treated with primary hormonal therapy was 
investigated using the Androgen Deficiency in Aging Male (ADAM) questionnaire to allow 
comparison with healthy aged men who visited the institution to for medical examinations. 
Surprisingly, the QOL of men receiving primary hormonal therapy was rather better than that of the 
healthy controls, except for sexual function in men aged 50 – 59 years19). Actually, most prostate 
cancer patients reported no anxiety regarding their primary disease or side effects of the treatment. 
Kato et al. evaluated health-related QOL (HRQOL) in Japanese men receiving hormonal therapy for 
prostate cancer using SF-36 and USLA-PCI20). They concluded that general HRQOL was mostly 
unaffected by hormonal therapy and that most patients did not report sexual bother despite 
deterioration of sexual function. These reports suggest that QOL of prostatic cancer patients 
receiving hormonal therapy is rather better than previously thought, at least in Japan. 
Medical costs can also be a significant issue. The medical cost of hormonal therapy is higher 
than those of other treatments, but there are costs that are calculated directly, such as medical costs 
or transportation for hospital visits, and costs that cannot be calculated, such as loss of employment 
for disease treatment or psychological burden. Therefore, estimation of cost is very difficult, and 
further studies are required to compare costs with those of other types of treatment. 
 
Role of hormonal therapy for high-risk or locally advanced localized prostate cancer 
Patients with high-risk or locally advanced prostate cancer with high Gleason score, elevated 
PSA level, and advanced clinical stage have a high probability of treatment failure after initial 
management by single-treatment modalities, such as hormonal therapy21), radical prostatectomy, 
external beam radiation therapy (EBRT), or brachytherapy22, 23). Therefore, it is extremely important 
to establish the most effective treatment strategy for patients with high-risk prostate cancer. As 
high-risk patients may have locally advanced disease with direct extension and/or micrometastases, 
various combinations of treatments have been developed to augment cancer-specific survival. 
Neoadjuvant and/or adjuvant hormonal therapy offer synergistic enhancement of radiation therapy or 
radical prostatectomy due to induction of apoptosis. Moreover, hormonal therapy may play a role in 
elimination of occult systemic disease24, 25). Whereas many studies have demonstrated benefits of 
hormonal therapy used in conjunction with EBRT to treat locally advanced prostate cancer26- 30), 
questions and criticisms remain, including the details of the duration, timing, and contents of 
hormonal therapy. The results of radiation oncology group trial (RTOG)-9202 regarding 
effectiveness and adverse effects of hormone therapy are very informative31). These results suggest 
that cause-specific benefits of hormone therapy may have been offset by deaths from other causes 
induced by hormone therapy. 
As the prolonged use of hormonal therapy results in increased incidence rates of adverse events, 
investigation of the optimal duration of hormonal therapy with maximization of clinical outcome and 
minimization of toxicity is a logical step in the management of localized high-risk prostate cancer. 
Further, we determine which patients with high risk prostate cancer will actually benefit from 
hormonal therapy even if there is some compromise in QOL associated with the adverse event 
profile of this treatment. Trials regarding adjuvant hormonal therapy have already demonstrated the 
superiority of longer periods of adjuvant hormonal therapy29). Therefore, with sufficient care to 
prevent adverse effects due to hormonal therapy, better outcomes with further longer neoadjuvant 
hormonal therapy may be achieved. tri-modality treatment (EBRT + brachytherapy ± hormonal 
therapy) has attracted attention as another method to produce better outcomes in cases of high-risk 
prostate cancer32). According to the American Brachytherapy Society (ABS), brachytherapy alone is 
not recommended for high-risk prostate cancer but can be used as a boost in conjunction with 
EBRT33). In this multimodal approach, combined brachytherapy and EBRT theoretically delivers a 
possible escalated dose to the prostate and at the same time to extracapsular cancer extension. 
Although the ABS provides no clear indications for neoadjuvant and/or adjuvant hormonal therapy 
with combination of brachytherapy and EBRT in high-risk prostate cancer, the duration of hormonal 
therapy could be reduced with such multi-modality radiotherapy. 
In contrast to the many efforts to develop better treatments for radiotherapy with hormonal 
therapy, there have been few clinical trials investigating the effectiveness of neoadjuvant or adjuvant 
hormonal therapy with radical prostatectomy34). One reason for this is that early studies of 
neoadjuvant hormonal therapy did not confirm the improvement of overall survival despite 
improvements in the pathological findings. Another reason is that surgeons may have less interest in 
medical treatments, such as hormonal therapy. However, surgeons should consider the best methods 
of improving the results in cases of high-risk prostate cancer, because recent reports have indicated 
the superiority of radiotherapy for high-risk prostate cancer compared with radical prostatectomy35). 
Recently Dorff TB, et al reported that 2 years of adjuvant androgen deprivation therapy (ADT) after 
radical prostatectomy resulted in an extremely low rate of disease recurrence and prostate 
cancer-specific death for high-risk patients in SWOG S9921 Study36). 
Finally, it should be stressed that it may be possible to eradicate high-risk or locally advanced 
prostate cancer with appropriate use of hormonal therapy in combination with radiotherapy or 
radical prostatectomy. Therefore, further well-designed clinical trials are required.  
 
Role of hormonal therapy in advanced prostate cancer 
At present, hormonal therapy is still used as the primary treatment for advanced prostate cancer. 
However, the methods of hormonal therapy, castration alone, antiandrogen agents alone, or CAB, are 
not necessarily the same. This makes the evaluation of hormonal therapy confusing. CAB consisting 
of ADT with LH-RH analog and antiandrogen agents has replaced surgical castration and estrogen 
agents. In prostate cancer cells, dihydrotestosterone (DHT) is converted from testosterone produced 
in the testis. DHT which binds with androgen receptor (AR) in the nuclei of prostate cancer cells 
activates androgen-responsive genes, and finally plays a major role in the proliferation of prostate 
cancer cells. Androgen deprivation by LH-RH analog or surgical castration induces apoptosis of 
prostate cancer cells, and the treatment effect for prostate cancer is put out clinically. On the other 
hand, testosterone and DHT are also converted from dehydroepiandrosterone (DHEA) and 
androstenedione secreted from the adrenal gland, and it has been reported that approximately 40% of 
androgen in prostate tissue is derived from the adrenal gland37). Moreover, we showed that 
approximately 25% of testosterone in prostate cancer tissue remained after castration38). These 
results suggested that ADT for prostate cancer requires not only surgical or medical castration using 
LH-RH analog but also antiandrogen agents. Antiandrogen agents block the activities of androgens 
by various mechanisms. Therefore, it is possible that the different clinical outcomes of CAB 
treatment are due to the various kinds of antiandrogen agents used39). 
Recently, the results of a phase 3 randomized controlled trial of CAB in advanced prostate cancer 
showed that LH-RH analog + 80 mg of bicalutamide was more effective than LH-RH analog alone, 
with favorable safety profiles and cost-effectiveness and without deterioration of QOL40). Although 
the effectiveness of CAB treatment has been confirmed, most patients with advanced prostate cancer 
unfortunately experience relapse, which has been named hormone refractory prostate cancer (HRPC). 
To such relapsed prostate cancer after primary ADT failure chemotherapy using docetaxel could be 
used as the standard treatment. One the other hand other modalities of hormonal therapy using other 
antiandrogen agents41), glucocorticoids, estrogens, or ketoconazole could be used as the second or 
third hormonal therapy and have frequently been effective in so-called HRPC. Therefore, HRPC was 
shown to be not necessarily hormone independent, and therefore it has been renamed 
castration-resistant prostate cancer (CRPC). The mechanisms of CRPC are thought to be as follows. 
First, these lesions are thought to have higher sensitivity of AR to androgen. AR signaling could be 
amplified by AR overexpression, AR mutations, or changes in AR-interactive factors, such as 
cofactors. With such higher sensitivity of AR, even low levels androgen can induce AR activation. 
The second mechanism of CRPC is intraprostatic formation of androgens. As mentioned above37, 38), 
approximately 25% – 40% of DHT remains in castrated prostate tissue in which enzymes that 
convert progesterone to androgen were shown to be overexpressed. This DHT is converted from 
precursor steroids, which are derived from the adrenal gland and peripheral tissues. This relatively 
low concentration of DHT may be sufficient to stimulate AR signaling via increased sensitivity of 
AR.  
Given the several mechanisms of action of CRPC42), the clinical development of novel agents is 
still ongoing. MDV3100 is a novel second generation antiandrogen. MDV3100 has greater binding 
affinity for AR to inhibit DNA binding of androgens to AR40). MDV3100 also inhibits nuclear 
translocation of androgens. In a phase 1/2 multicenter study of 140 patients with CRPC, MDV3100 
showed overall ≥ 50% PSA decrease in 56% of patients44).  
Another target in CRPC is inhibition of androgen biosynthesis in prostatic cancer tissues. 
Inhibition of CYP17 is promising, because upregulation of CYP17 expression has been 
demonstrated in CRPC tissues45). CYP17 catalyzes two essential reactions in androgen biosynthesis, 
17a-hydroxylase and C17, 20 lyase. Three novel selective inhibitors of CYP17 are currently under 
development. As abiraterone acetate inhibits both 17a-hydroxylase and C17, 20 lyase, glucocorticoid 
replacement is necessary. Clinical trials to compare the effectiveness of abiraterone plus prednisone 
with those of prednisone plus placebo in CRPC patients previously treated with docetaxel are 
currently underway. Interim analysis demonstrated significant improvement of overall survival in 
patients treated with abiraterone plus prednisone46, 47). TAK-700 is a more selective inhibitor of 
CYP17, because inhibition of C17, 20 lyase is more potent than that of 17a-hydroxylase48). Thus, 
glucocorticoid replacement may be unnecessary or only minimal glucocorticoid replacement may be 
required in compared to patients treated with abiraterone. Phase 1/2 studies of TAK-700 are 
currently underway. TOK-001 (previously VN/124-1) is also a selective inhibitor of CYP1749). This 
compound could also downregulate AR expression. Other compounds targeting intact or truncated 
AR are also under investigation. 
 
Issues of adverse effects 
Several recent studies indicated that ADT increases the incidences of cardiovascular disease and 
bone fractures. Keating et al. demonstrated that GnRH agonist increased the risk of diabetes mellitus 
(DM), coronary heart disease (CHD), myocardial infarction, and sudden cardiac death compared 
with the risks in patients without hormonal therapy50). However, their paper had some limitations. 
First, this was not a randomized study. Therefore, patients receiving GnRH agonist may have been 
associated with higher levels of background factors contributing to DM or heart disease. For 
example, older men who are more likely to receive hormonal therapy are also likely to develop DM 
or CHD. Second, we cannot exclude the possibility that men receiving regular injection were more 
likely to be diagnosed with DM or CHD because of the greater frequency of medical consultations. 
D’Amico et al. showed that a subset of men age 65 years or older who received 6 months of ADT 
demonstrated shorter intervals to fatal myocardial infarctions compared with men in this age group 
who did not receive ADT51). However, this paper was criticized by the authors of another paper 
recently published in the same journal52). One major criticism was that D’Amico et al. did not show 
any difference in total number of fatal myocardial infarctions between groups. Their study was also 
criticized for its short treatment duration, shorter follow-up, and the lack of information on 
cardiovascular disease (CVD) risk factors. Efstatiou et al. described the first analysis using data from 
a large prospective study to directly address the potential relationship between GnRH agonists and 
cardiovascular mortality52). In this study, patients with locally advanced prostate cancer who selected 
radiotherapy were randomly assigned to one of two arms. Patients in arm 1 received radiotherapy 
plus adjuvant hormonal therapy for 4.2 years on average. Those in arm 2 initially received only 
radiotherapy, and thereafter 64% of patients received salvage hormonal therapy after recurrence. 
Pretreatment characteristics, including CVD risk factors, were similar between the two arms. 
Surprisingly, at 9 years, cardiovascular mortality rate for men treated with adjuvant hormonal 
therapy was 8.4%, which was less than the rate of 11.4% for men without adjuvant hormonal therapy. 
However, patients with established CVD risk factors were significantly associated with greater 
cardiovascular mortality. Therefore, criticism of hormonal therapy should not be simplistic, but 
rather should focus on decreasing cardiovascular risk factors and managing CVD. 
With regard to the adverse effects of hormonal therapy data for the general population show that 
the incidence of ischemic heart disease is much lower in Japanese than in Westerners. For bone 
fractures, the incidence is much lower in Japanese than in Western populations. Based on these data, 
we expect that the adverse effects of hormonal therapy will be less in Japanese populations. Akaza et 
al. conducted the J-CaP study as a surveillance study of hormonal therapy in Japan53). The data 
showed that the cardiovascular mortality rate in Japanese patients undergoing ADT was almost the 
same as the rate in the general population, as expected. Nevertheless, androgen deprivation could 
induce a variety of adverse effects even in Japan, because the adoption of a more western life-style 
may increase the susceptibility to adverse effects by hormonal therapy. Therefore, efforts should be 
made to prevent or decrease such adverse effects as much as possible. Management strategies for 
ADT-associated morbidities are shown in Table 1. It is well known that bone mineral density is 
decreased during long-term ADT. Therefore, the fracture rate after ADT is not low. We performed a 
nonrandomized prospective study to confirm the usefulness of bisphosphonate for improvement of 
the bone mineral density of patients receiving hormonal therapy54). Whereas bone mineral densities 
of patients not receiving risedronate continued to decrease, those of patients receiving risedronate 
increased. Management of endocrine and metabolic dysfunctions, such as DM, is very important, 
although most urologists do not pay adequate attention to such nonsurgical issues. Androgen 
deficiency is now attracting attention as one of the causes of metabolic syndrome. Basaria et al. 
reported that hormonal therapy induces metabolic syndrome They detected metabolic syndrome in 
more than 50% of men receiving long-term ADT55). Therefore, we should carefully manage patients 
receiving hormonal therapy, and this is not as difficult as performing complicated surgery. The 
Endocrine Society Clinical Practice Guidelines will be helpful in preventing cardiovascular disease 
and DM. Furthermore, we should make our own clinical guidelines for urologists managing prostate 
cancer patients with hormonal therapy. 
 
Issues related to patient satisfaction 
The Prostate Cancer Outcome Study yielded interesting results56). In this study patients’ 
satisfaction was compared after each treatment; watchful waiting, primary androgen deprivation, 
radiotherapy, and radical prostatectomy. Satisfaction was higher in men receiving primary ADT than 
in those managed by watchful waiting or radical prostatectomy. In addition, most patients indicated 
that they would make the same choice if they had to select the treatment again. Thus, in patients 
requiring hormonal therapy, criticism of primary ADT should not be simplistic, but rather efforts 
should focus on decreasing its adverse effects.  
 
Conclusion  
Hormonal therapy has played as important role in the treatment of prostate cancer since it was 
first introduced about 70 years ago by Huggins and Hodges1). Recently, however, hormonal therapy 
has been the subject of frequent criticism. Some authors reported that it showed minimal 
effectiveness, while others suggested that it may reduce patients’ QOL and induce adverse effects. 
Such reports should be evaluated very carefully57). From Japanese experiences using hormonal 
therapy we suspect that there may be ethnic differences in efficacy and adverse effects of hormonal 
therapy. Therefore, it is necessary to accumulate further clinical evidence concerning the efficacy 
and adverse effects of hormonal therapy. We should also strive to decrease its adverse effects, 
because life-style change may increase the susceptibility to adverse effects by hormonal therapy 
even in Japan. New hormonal compounds such as selective androgen receptor modulator (SARM) 
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Fig 1. Comparison of the efficacy of hormonal therapy between Japanese-American  
and caucasians living in Hawaii  （modified from reference 7） 
 
Fig. 2. Disease-specific survival rates of low-, intermediate-, high-risk groups treated 
 with primary androgen deprivation therapy  (cited from reference 13) 
 
Fig. 3. Treatment algorithm for patients with low- and intermediate-risk localized 
 prostate cancer   (cited from reference 13) 
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Fig 1. Comparison of the efficacy of Hormonal Therapy 
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Table 1. Management strategies for ADT-associated morbidities
Complication Management Strategy
Cardiovascular risk factors 
and disease
1) Non-smoking
2) Consultation for diet and exercise
3) Regular monitoring of serum lipid profiles
Osteoporosis and fractures 1)  Regular monitoring of BMD 
2)  Consultation for exercise, diet with adequate calcium  and Vit 
D intake
3)  Bisphosphonates 
Endocrine and  metabolic 
dysfunction
1) Consultation for nutrition, exercise, and  weight control prior 
to ADT 
2) Regular monitoring of HbA1c and fasting blood sugar 
Hot flash 1) Chlormadinone acetate 
2) SSRI
Sexual Dysfunction 1)  PDE-5 inhibitors 
2)  Cavernous injection of PGE-1 
3)  Vacuum erection devices
